TRIFLURIDINE & TIPIRACIL

TRIFLURIDINE & TIPIRACIL

Tablets

TRIFLURIDINE & TIPIRACIL 15 MG AND 20 MG TABLETS
"LONSURF contains trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5. Each film-coated tablet of LONSURF, for oral use, contains 20 mg of trifluridine and 8.19 mg of tipiracil equivalent to 9.420 mg of tipiracil hydrochloride as active ingredients. LONSURF tablets contain the following inactive ingredients: lactose monohydrate, pregelatinized starch, stearic acid, hypromellose, polyethylene glycol, titanium dioxide, ferric oxide, and magnesium stearate. Both film-coated tablets (LONSURF 15 mg/6.14 mg and 20 mg/8.19 mg) are imprinted with ink containing shellac, ferric oxide red, ferric oxide yellow, titanium dioxide, FD&C Blue No. 2 Aluminum Lake, carnauba wax, and talc. "
Tablets Lonsurf - • 15 mg trifluridine/6.14 mg tipiracil • 20 mg trifluridine/8.19 mg tipiracil
Recommended dosage: 35 mg/m2 /dose orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. • Take LONSURF within 1 hour after completion of morning and evening meals.
LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.